论文部分内容阅读
目的:比较阿托伐他汀和辛伐他汀对急性冠状动脉综合征(ACS)患者早期强化调脂、抗炎作用及安全性。方法:将92例ACS患者随机分成阿托伐他汀组(A组,阿托伐他汀40mg,qn)和辛伐他汀组(B组,辛伐他汀40mg,qn),服药前及服药4、8周测定TC、LDL-C、TG、超敏C反应蛋白(hs-CRP)、谷丙转氨酶(ALT)、谷草转氨酶(AST),并随访1年,记录主要心脑血管事件和药物不良反应。结果:①治疗4、8周后2组TC、LDL-C、TG及hs-CRP均明显降低(P<0.05),组间差异无统计学意义(P>0.05);②2组疗效差异无统计学意义(P>0.05);③2组均能有效降低主要心脑血管事件,组间差异无统计学意义(P>0.05);④2者对肝酶的影响和药物相关不良反应发生率低,差异无统计学意义(P>0.05)。结论:阿托伐他汀和辛伐他汀强化治疗均能显著降低ACS患者的TC、LDL-C、TG、以及hs-CRP水平,疗效和不良反应无差异,具有良好的安全性。
Objective: To compare atherosclerosis and antihypertensive effects of atorvastatin and simvastatin in patients with acute coronary syndrome (ACS). Methods: A total of 92 patients with ACS were randomly divided into atorvastatin group (group A, atorvastatin 40 mg, qn) and simvastatin group (group B, simvastatin 40 mg, qn) The levels of TC, LDL-C, TG, hs-CRP, ALT, AST were measured weekly and followed up for one year. Cardiovascular events and adverse drug reactions were recorded. Results: ① At 4 and 8 weeks after treatment, TC, LDL-C, TG and hs-CRP in two groups were significantly decreased (P <0.05), but there was no significant difference between two groups (P> 0.05) (P> 0.05); ③The two groups can effectively reduce the major cardiovascular events, the difference was not statistically significant (P> 0.05); ④ 2 of the liver enzymes and drug-related adverse reactions, the incidence was low, the difference No statistical significance (P> 0.05). Conclusion: Both atorvastatin and simvastatin can significantly reduce the levels of TC, LDL-C, TG and hs-CRP in patients with ACS. There is no difference between the two groups in efficacy and adverse reactions, and they have good safety.